Prostate Cancer Trial, Recruiting (NCT07290270)

Prostate Cancer Trial, Recruiting NCT07290270 Sponsor: Novartis Pharmaceuticals Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07290270 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults who are male and have been diagnosed with either metastatic castration-resistant prostate cancer (a form of prostate cancer that has spread and no longer responds to hormone therapy) or metastatic hormone-sensitive prostate cancer (a form of prostate cancer that has spread but still responds to hormone therapy)
People whose treating doctor has decided to start them on a specific radioligand therapy called lutetium-177 PSMA (brand name: Pluvicto) as part of their standard treatment plan
People who enroll either before their first treatment session or within 2 weeks after their first treatment session
People who have signed a written consent form before any information is collected from them
People whose organ function meets the standards set out by the Society of Nuclear Medicine and Molecular Imaging guidelines (confirm with trial site)

Who may not be able to join:

People who are currently taking part in another clinical trial or another Novartis-sponsored observational study also involving lutetium-177 PSMA at the same time as this study
Other criteria set out in the study protocol may also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07290270

Sponsor: Novartis Pharmaceuticals

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

Trial contact: +41613241111

More information: https://clinicaltrials.gov/study/NCT07290270

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults who are male and have been diagnosed with either metastatic castration-resistant prostate cancer (a form of prostate cancer that has spread and no longer responds to hormone therapy) or metastatic hormone-sensitive prostate cancer (a form of prostate cancer that has spread but still responds to hormone therapy)
People whose treating doctor has decided to start them on a specific radioligand therapy called lutetium-177 PSMA (brand name: Pluvicto) as part of their standard treatment plan
People who enroll either before their first treatment session or within 2 weeks after their first treatment session
People who have signed a written consent form before any information is collected from them
People whose organ function meets the standards set out by the Society of Nuclear Medicine and Molecular Imaging guidelines (confirm with trial site)

Who may not be able to join:

People who are currently taking part in another clinical trial or another Novartis-sponsored observational study also involving lutetium-177 PSMA at the same time as this study
Other criteria set out in the study protocol may also apply (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Novartis Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

4 February 2026

Est. completion

31 August 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

prostate-specific antigen (PSA) 50 response rate; prostate-specific antigen (PSA) 90 response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov